None of the patients harboring a K-Ras mutant tumor achieved an objective response to erlotinib compared with 10 out of 30 wild-type patients evaluable for the analysis (RR: 0% vs. 33%; p = 0.296): of these 10 K-Ras wild-type patients, 8 harbored an EGFR mutant tumor. The gene discussed is EGFR; the disease is neoplasm.